China’s Healthcare Sector Under Scrutiny: Price Gouging, Collusion,and Regulatory Crackdown
Beijing, August 25, 2024 – The Chinese healthcare sector is facing a wave of regulatory scrutiny, with authorities cracking down on price gouging, collusion, and other unethical practices.This week alone, several companies have been penalized for their actions, highlighting the government’s commitment to ensuring fair and transparent pricing in the healthcare market.
Price Gouging and Collusion: Six Companies Blacklisted for 6 Months
The National Healthcare Security Administration (NHSA) announced the punishment of six companies involved in a bid-rigging scheme during the seventh round of national centralized drugprocurement. Guangzhou Yipinhong, Shijiazhuang Siyao, and four other companies were found to have colluded to manipulate the bidding process for the drug Bromhexine Hydrochloride Injection.
The NHSA investigation revealed thatthe companies, along with a group of individuals and distributors, had pre-determined the winning and losing bidders, ultimately resulting in inflated prices and losses for the healthcare security fund.
As a consequence, Yipinhong, Siyao, Chengdu Xinjie, and Renhe Yikang were blacklisted for sixmonths, while Chengdu Xinjie, Shanghai Xudong Haipu, and Jiangxi Yiyou were banned for a year. The NHSA also recovered the excess funds from the companies and mandated price reductions for Bromhexine Hydrochloride Injection and other drugs.
Castor Stent Price Under Scrutiny: Heart MedicalDevice Company Forced to Cut Prices
In another instance of price gouging, the NHSA launched an investigation into the pricing of the Castor Thoracic Aortic Covered Stent and Delivery System, manufactured by Shanghai MicroPort Heart Medical. The stent, priced at approximately 50,000 yuan (USD7,000) at the factory, was sold to medical institutions at over 120,000 yuan (USD 17,000) through distributors.
Following the NHSA’s inquiry, MicroPort Heart Medical announced a price reduction for the Castor stent, bringing theprice down to around 70,000 yuan (USD 10,000).
Regulatory Scrutiny Extends to Acquisitions and IPOs
The NHSA’s focus on ethical practices extends beyond price manipulation. The agency is also scrutinizing acquisitions and initial public offerings (IPOs) in the healthcare sector.
Tongyuan Kang Pharmaceutical, a company specializing in the development and production of innovative drugs, recently listed on the Hong Kong Stock Exchange. Meanwhile, a company that acquired another company with zero revenue at a premium price is facing regulatory scrutiny.
Piece Huang Temporarily SuspendsRelated Transactions
In a separate development, Piece Huang, a renowned Chinese pharmaceutical company, announced it would temporarily suspend related transactions following concerns raised by regulators. The company’s decision comes after an investigation into its acquisition of a company with zero revenue at a premium price.
Implications for the Healthcare Sector
Therecent crackdown on unethical practices in China’s healthcare sector sends a strong message to companies operating in the industry. The NHSA’s actions demonstrate the government’s commitment to ensuring fair and transparent pricing, promoting ethical business practices, and protecting the interests of patients and the healthcare security fund.
This regulatory scrutiny islikely to continue, with the NHSA expected to further investigate and address issues related to price manipulation, collusion, and other unethical practices. The healthcare sector is expected to adapt to this new regulatory environment, prioritizing transparency, ethical conduct, and patient well-being.
【来源】http://www.chinanews.com/life/2024/08-25/10274437.shtml
Views: 1